MONDAY, SEPTEMBER 26, 2016

TB Biosciences Board of Directors gains new member

TB Biosciences, Inc. announced on Thursday that David C. Oxley has joined the company's Board of Directors.

Oxley is vice president of emerging markets sales for Cytori Therapeutics, a public company engaged in the development, manufacture, and sales of medical technologies. In this position, Oxley is responsible for establishing Cytori subsidiaries and commercial sales and distribution activities across Latin America, Africa, India and other countries.

Prior to his position at Cytori, Oxley was executive vice president of worldwide sales and marketing for the Point-of-Care Division of Trinity Biotech. Oxley was also head of government affairs at OraSure Technologies and a delegate of the Private Sector Delegation to the Board of the Global Fund to Fight HIV, TB and Malaria.

"We are extremely pleased to have David join the TB Biosciences' board," Sam Niedbala, CEO and co-founder of TB Biosciences, said. "As the Company works to develop a rapid point-of-care tuberculosis test that meets performance standards around the world, we are confident that David's expertise and experience in developing and commercializing point-of-care diagnostic tests will be a valuable addition to our board."

TB Biosciences is a Bethlehem, Pennsylvania based early stage development medical diagnostics company that was founded in June to make a rapid point-of-care tuberculosis test.